You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLumefantrine
Accession NumberDB06708
TypeSmall Molecule
GroupsApproved
DescriptionLumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Structure
Thumb
Synonyms
(+-)-2,7-Dichloro-9-((Z)-P-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
Benflumetol
DL-Benflumelol
Lumefantrine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
CoartemNovartis Pharmaceuticals Corporation
SaltsNot Available
Categories
UNIIF38R0JR742
CAS number82186-77-4
WeightAverage: 528.94
Monoisotopic: 527.154947772
Chemical FormulaC30H32Cl3NO
InChI KeyInChIKey=DYLGFOYVTXJFJP-MYYYXRDXSA-N
InChI
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
IUPAC Name
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol
SMILES
CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationLumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
PharmacodynamicsLumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. It is thought that administration of lumefantrine with artemether results in cooperate antimalarial clearing effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thus thought to provide rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Mechanism of actionThe exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.
Related Articles
AbsorptionFood increases absorption.
Volume of distributionNot Available
Protein binding99.7% bound
Metabolism

Extensively metabolized in the liver primarily by cytochrome P450 3A4. The major metabolite found in plasma is desbutyl-lumefantrine.

SubstrateEnzymesProduct
Lumefantrine
desbutyl-lumefantrineDetails
Route of eliminationNot Available
Half life~ 4.5 days
ClearanceNot Available
ToxicityCommon side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9363
Caco-2 permeable+0.6319
P-glycoprotein substrateSubstrate0.8389
P-glycoprotein inhibitor IInhibitor0.6854
P-glycoprotein inhibitor IINon-inhibitor0.5475
Renal organic cation transporterInhibitor0.5792
CYP450 2C9 substrateNon-substrate0.7971
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7076
CYP450 1A2 substrateInhibitor0.6872
CYP450 2C9 inhibitorNon-inhibitor0.7112
CYP450 2D6 inhibitorInhibitor0.7727
CYP450 2C19 inhibitorNon-inhibitor0.6525
CYP450 3A4 inhibitorNon-inhibitor0.6983
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7168
Ames testNon AMES toxic0.6424
CarcinogenicityNon-carcinogens0.7629
BiodegradationNot ready biodegradable0.9924
Rat acute toxicity2.4077 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7654
hERG inhibition (predictor II)Inhibitor0.776
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility3.09e-05 mg/mLALOGPS
logP8.34ALOGPS
logP9.19ChemAxon
logS-7.2ALOGPS
pKa (Strongest Acidic)14.1ChemAxon
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity160.81 m3·mol-1ChemAxon
Polarizability60.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesP01BF01
AHFS Codes
  • 8:30.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lumefantrine.
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when 5'-Deoxy-5'-Methylthioadenosine is combined with Lumefantrine.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Lumefantrine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lumefantrine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lumefantrine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lumefantrine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Lumefantrine.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Lumefantrine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Lumefantrine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Lumefantrine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lumefantrine.
AmantadineAmantadine may increase the QTc-prolonging activities of Lumefantrine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lumefantrine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Lumefantrine.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Lumefantrine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Lumefantrine.
AmodiaquineThe risk or severity of adverse effects can be increased when Amodiaquine is combined with Lumefantrine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Lumefantrine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Lumefantrine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lumefantrine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lumefantrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lumefantrine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Lumefantrine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lumefantrine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Lumefantrine.
AprepitantThe serum concentration of Lumefantrine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Lumefantrine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Lumefantrine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Lumefantrine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lumefantrine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Lumefantrine.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Lumefantrine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lumefantrine.
ArtemetherLumefantrine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe risk or severity of adverse effects can be increased when Artesunate is combined with Lumefantrine.
AsenapineAsenapine may increase the QTc-prolonging activities of Lumefantrine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Lumefantrine.
AtazanavirThe serum concentration of Lumefantrine can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Lumefantrine can be decreased when combined with Atomoxetine.
AtovaquoneThe risk or severity of adverse effects can be increased when Atovaquone is combined with Lumefantrine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Lumefantrine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Lumefantrine.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Lumefantrine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Lumefantrine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lumefantrine.
BepridilThe metabolism of Bepridil can be decreased when combined with Lumefantrine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Lumefantrine.
BexaroteneThe serum concentration of Lumefantrine can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lumefantrine.
BoceprevirThe serum concentration of Lumefantrine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Lumefantrine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Lumefantrine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lumefantrine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lumefantrine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lumefantrine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lumefantrine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lumefantrine.
BupropionThe metabolism of Bupropion can be decreased when combined with Lumefantrine.
BuserelinBuserelin may increase the QTc-prolonging activities of Lumefantrine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Lumefantrine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Lumefantrine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Lumefantrine.
CarbamazepineThe serum concentration of Lumefantrine can be decreased when it is combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lumefantrine.
CarteololThe metabolism of Carteolol can be decreased when combined with Lumefantrine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lumefantrine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lumefantrine.
CeritinibCeritinib may increase the QTc-prolonging activities of Lumefantrine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lumefantrine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lumefantrine.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumefantrine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Lumefantrine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lumefantrine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Lumefantrine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Lumefantrine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lumefantrine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Lumefantrine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lumefantrine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Lumefantrine.
CisaprideCisapride may increase the QTc-prolonging activities of Lumefantrine.
CitalopramCitalopram may increase the QTc-prolonging activities of Lumefantrine.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Lumefantrine.
ClemastineThe metabolism of Lumefantrine can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.
ClomipramineClomipramine may increase the QTc-prolonging activities of Lumefantrine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Lumefantrine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Lumefantrine.
ClotrimazoleThe metabolism of Lumefantrine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Lumefantrine.
ClozapineThe metabolism of Clozapine can be decreased when combined with Lumefantrine.
CobicistatThe serum concentration of Lumefantrine can be increased when it is combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lumefantrine.
ConivaptanThe serum concentration of Lumefantrine can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Lumefantrine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Lumefantrine.
CyclosporineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lumefantrine.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Lumefantrine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lumefantrine.
DarunavirThe serum concentration of Lumefantrine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lumefantrine.
DasatinibThe serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Lumefantrine.
DeferasiroxThe serum concentration of Lumefantrine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Lumefantrine.
DelavirdineThe metabolism of Lumefantrine can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Lumefantrine.
DesipramineDesipramine may increase the QTc-prolonging activities of Lumefantrine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Lumefantrine.
DexamethasoneThe serum concentration of Lumefantrine can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lumefantrine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Lumefantrine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lumefantrine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lumefantrine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lumefantrine.
DihydroergotamineThe metabolism of Lumefantrine can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Lumefantrine can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Lumefantrine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Lumefantrine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Lumefantrine.
DofetilideDofetilide may increase the QTc-prolonging activities of Lumefantrine.
DolasetronDolasetron may increase the QTc-prolonging activities of Lumefantrine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Lumefantrine.
DomperidoneDomperidone may increase the QTc-prolonging activities of Lumefantrine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Lumefantrine.
DopamineThe metabolism of Dopamine can be decreased when combined with Lumefantrine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Lumefantrine.
DoxepinDoxepin may increase the QTc-prolonging activities of Lumefantrine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Lumefantrine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lumefantrine.
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Lumefantrine.
DronedaroneDronedarone may increase the QTc-prolonging activities of Lumefantrine.
DroperidolDroperidol may increase the QTc-prolonging activities of Lumefantrine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Lumefantrine.
EfavirenzThe serum concentration of Lumefantrine can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Lumefantrine.
EliglustatLumefantrine may increase the QTc-prolonging activities of Eliglustat.
EncainideThe metabolism of Encainide can be decreased when combined with Lumefantrine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lumefantrine.
EnzalutamideThe serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Lumefantrine.
EribulinEribulin may increase the QTc-prolonging activities of Lumefantrine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Lumefantrine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Lumefantrine.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Lumefantrine.
Eslicarbazepine acetateThe serum concentration of Lumefantrine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Lumefantrine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lumefantrine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lumefantrine.
EtravirineThe serum concentration of Lumefantrine can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Lumefantrine.
FamotidineFamotidine may increase the QTc-prolonging activities of Lumefantrine.
FelbamateFelbamate may increase the QTc-prolonging activities of Lumefantrine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.
FingolimodFingolimod may increase the QTc-prolonging activities of Lumefantrine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lumefantrine.
FlecainideFlecainide may increase the QTc-prolonging activities of Lumefantrine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Lumefantrine.
FluconazoleThe metabolism of Lumefantrine can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lumefantrine.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Lumefantrine.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Lumefantrine.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Lumefantrine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lumefantrine.
FluvoxamineThe metabolism of Lumefantrine can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Lumefantrine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Lumefantrine.
FosamprenavirThe metabolism of Lumefantrine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Lumefantrine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Lumefantrine.
FosphenytoinThe serum concentration of Lumefantrine can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Lumefantrine can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Lumefantrine.
GalantamineGalantamine may increase the QTc-prolonging activities of Lumefantrine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Lumefantrine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lumefantrine.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Lumefantrine.
GoserelinGoserelin may increase the QTc-prolonging activities of Lumefantrine.
GranisetronGranisetron may increase the QTc-prolonging activities of Lumefantrine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Lumefantrine.
HalofantrineThe risk or severity of adverse effects can be increased when Halofantrine is combined with Lumefantrine.
HalofantrineLumefantrine may increase the QTc-prolonging activities of Halofantrine.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Lumefantrine.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Lumefantrine.
HalothaneThe metabolism of Halothane can be decreased when combined with Lumefantrine.
HistrelinHistrelin may increase the QTc-prolonging activities of Lumefantrine.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Lumefantrine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lumefantrine.
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Lumefantrine.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Lumefantrine.
IbandronateIbandronate may increase the QTc-prolonging activities of Lumefantrine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Lumefantrine.
IbutilideIbutilide may increase the QTc-prolonging activities of Lumefantrine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lumefantrine.
IdelalisibThe serum concentration of Lumefantrine can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the QTc-prolonging activities of Lumefantrine.
ImatinibThe metabolism of Lumefantrine can be decreased when combined with Imatinib.
ImipramineImipramine may increase the QTc-prolonging activities of Lumefantrine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Lumefantrine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Lumefantrine.
IndapamideIndapamide may increase the QTc-prolonging activities of Lumefantrine.
IndinavirThe serum concentration of Lumefantrine can be increased when it is combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.
IsavuconazoniumThe metabolism of Lumefantrine can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Lumefantrine.
IsradipineThe metabolism of Lumefantrine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Lumefantrine.
IvacaftorThe serum concentration of Lumefantrine can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lumefantrine.
KetoconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Lumefantrine.
LapatinibLapatinib may increase the QTc-prolonging activities of Lumefantrine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Lumefantrine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lumefantrine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Lumefantrine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Lumefantrine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Lumefantrine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lumefantrine.
LisurideThe metabolism of Lisuride can be decreased when combined with Lumefantrine.
LithiumLithium may increase the QTc-prolonging activities of Lumefantrine.
LomustineThe metabolism of Lomustine can be decreased when combined with Lumefantrine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Lumefantrine.
LopinavirLopinavir may increase the QTc-prolonging activities of Lumefantrine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Lumefantrine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lumefantrine.
LovastatinThe metabolism of Lumefantrine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Luliconazole.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Lumefantrine.
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Lumefantrine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lumefantrine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Lumefantrine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Lumefantrine.
MethadoneMethadone may increase the QTc-prolonging activities of Lumefantrine.
MethadoneThe metabolism of Methadone can be decreased when combined with Lumefantrine.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lumefantrine.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Lumefantrine.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Lumefantrine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lumefantrine.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Lumefantrine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Lumefantrine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lumefantrine.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Lumefantrine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Lumefantrine.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Lumefantrine.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Lumefantrine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lumefantrine.
MianserinThe metabolism of Mianserin can be decreased when combined with Lumefantrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Lumefantrine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Lumefantrine.
MirabegronMirabegron may increase the QTc-prolonging activities of Lumefantrine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Lumefantrine.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Lumefantrine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Lumefantrine.
MitotaneThe serum concentration of Lumefantrine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lumefantrine.
ModafinilThe serum concentration of Lumefantrine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Lumefantrine.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Lumefantrine.
MorphineThe metabolism of Morphine can be decreased when combined with Lumefantrine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Lumefantrine.
NafcillinThe serum concentration of Lumefantrine can be decreased when it is combined with Nafcillin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lumefantrine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lumefantrine.
NefazodoneThe serum concentration of Lumefantrine can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Lumefantrine.
NelfinavirThe serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Lumefantrine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Lumefantrine.
NevirapineThe serum concentration of Lumefantrine can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Lumefantrine.
NicardipineNicardipine may increase the QTc-prolonging activities of Lumefantrine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Lumefantrine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Lumefantrine.
NicotineThe metabolism of Nicotine can be decreased when combined with Lumefantrine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lumefantrine.
NilotinibNilotinib may increase the QTc-prolonging activities of Lumefantrine.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Lumefantrine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lumefantrine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Lumefantrine.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Lumefantrine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lumefantrine.
OctreotideOctreotide may increase the QTc-prolonging activities of Lumefantrine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Lumefantrine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Lumefantrine.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Lumefantrine.
OlaparibThe metabolism of Lumefantrine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Lumefantrine.
OndansetronOndansetron may increase the QTc-prolonging activities of Lumefantrine.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Lumefantrine.
OsimertinibThe serum concentration of Lumefantrine can be increased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Lumefantrine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lumefantrine.
OxytocinOxytocin may increase the QTc-prolonging activities of Lumefantrine.
PalbociclibThe serum concentration of Lumefantrine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Lumefantrine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lumefantrine.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Lumefantrine.
ParoxetineParoxetine may increase the QTc-prolonging activities of Lumefantrine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Lumefantrine.
PasireotidePasireotide may increase the QTc-prolonging activities of Lumefantrine.
PazopanibPazopanib may increase the QTc-prolonging activities of Lumefantrine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Lumefantrine.
PentamidinePentamidine may increase the QTc-prolonging activities of Lumefantrine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lumefantrine.
PentobarbitalThe serum concentration of Lumefantrine can be decreased when it is combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Lumefantrine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lumefantrine.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Lumefantrine.
PethidineThe metabolism of Pethidine can be decreased when combined with Lumefantrine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lumefantrine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Lumefantrine.
PhenobarbitalThe serum concentration of Lumefantrine can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Lumefantrine can be decreased when it is combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Lumefantrine.
PindololThe metabolism of Pindolol can be decreased when combined with Lumefantrine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Lumefantrine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lumefantrine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Lumefantrine.
PosaconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Posaconazole.
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Lumefantrine.
PrimidoneThe serum concentration of Lumefantrine can be decreased when it is combined with Primidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Lumefantrine.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Lumefantrine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lumefantrine.
ProguanilThe risk or severity of adverse effects can be increased when Proguanil is combined with Lumefantrine.
PromazineThe serum concentration of Promazine can be increased when it is combined with Lumefantrine.
PromazinePromazine may increase the QTc-prolonging activities of Lumefantrine.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Lumefantrine.
PromethazinePromethazine may increase the QTc-prolonging activities of Lumefantrine.
PropafenonePropafenone may increase the QTc-prolonging activities of Lumefantrine.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Lumefantrine.
PropofolPropofol may increase the QTc-prolonging activities of Lumefantrine.
PropofolThe metabolism of Propofol can be decreased when combined with Lumefantrine.
PropranololThe metabolism of Propranolol can be decreased when combined with Lumefantrine.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Lumefantrine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Lumefantrine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Lumefantrine.
PyrimethamineThe risk or severity of adverse effects can be increased when Pyrimethamine is combined with Lumefantrine.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Lumefantrine.
QuinacrineThe risk or severity of adverse effects can be increased when Quinacrine is combined with Lumefantrine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Lumefantrine.
QuinidineLumefantrine may increase the QTc-prolonging activities of Quinidine.
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Lumefantrine.
QuinineLumefantrine may increase the QTc-prolonging activities of Quinine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lumefantrine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Lumefantrine.
RanolazineThe metabolism of Lumefantrine can be decreased when combined with Ranolazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Lumefantrine.
repinotanThe metabolism of repinotan can be decreased when combined with Lumefantrine.
RifabutinThe serum concentration of Lumefantrine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Lumefantrine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Lumefantrine can be decreased when it is combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Lumefantrine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Lumefantrine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Lumefantrine.
RitonavirThe serum concentration of Lumefantrine can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Lumefantrine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lumefantrine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lumefantrine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Lumefantrine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Lumefantrine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Lumefantrine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Lumefantrine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Lumefantrine.
SertralineSertraline may increase the QTc-prolonging activities of Lumefantrine.
SertralineThe metabolism of Sertraline can be decreased when combined with Lumefantrine.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Lumefantrine.
SildenafilThe metabolism of Lumefantrine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Lumefantrine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Lumefantrine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Lumefantrine.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lumefantrine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Lumefantrine.
SorafenibSorafenib may increase the QTc-prolonging activities of Lumefantrine.
SotalolSotalol may increase the QTc-prolonging activities of Lumefantrine.
SparteineThe metabolism of Sparteine can be decreased when combined with Lumefantrine.
St. John's WortThe serum concentration of Lumefantrine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Lumefantrine can be increased when it is combined with Stiripentol.
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Lumefantrine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Lumefantrine.
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Lumefantrine.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Lumefantrine.
SunitinibSunitinib may increase the QTc-prolonging activities of Lumefantrine.
tafenoquineThe risk or severity of adverse effects can be increased when tafenoquine is combined with Lumefantrine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Lumefantrine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Lumefantrine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Lumefantrine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lumefantrine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lumefantrine.
TelaprevirThe serum concentration of Lumefantrine can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Lumefantrine.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Lumefantrine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Lumefantrine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Lumefantrine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lumefantrine.
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Lumefantrine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lumefantrine.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Lumefantrine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lumefantrine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Lumefantrine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Lumefantrine.
TiclopidineThe metabolism of Lumefantrine can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Lumefantrine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lumefantrine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Lumefantrine.
TizanidineTizanidine may increase the QTc-prolonging activities of Lumefantrine.
TocilizumabThe serum concentration of Lumefantrine can be decreased when it is combined with Tocilizumab.
TolterodineTolterodine may increase the QTc-prolonging activities of Lumefantrine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Lumefantrine.
ToremifeneToremifene may increase the QTc-prolonging activities of Lumefantrine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Lumefantrine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lumefantrine.
TrazodoneTrazodone may increase the QTc-prolonging activities of Lumefantrine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Lumefantrine.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Lumefantrine.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine.
TrimethoprimThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Lumefantrine.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Lumefantrine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Lumefantrine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Lumefantrine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Lumefantrine.
VandetanibVandetanib may increase the QTc-prolonging activities of Lumefantrine.
VardenafilVardenafil may increase the QTc-prolonging activities of Lumefantrine.
VemurafenibLumefantrine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Lumefantrine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Lumefantrine can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Lumefantrine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Lumefantrine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Lumefantrine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lumefantrine.
VoriconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Lumefantrine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Lumefantrine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lumefantrine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lumefantrine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Lumefantrine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lumefantrine.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Lumefantrine.
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of lumefantrine and artemether.

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Comments
comments powered by Disqus
Drug created on May 15, 2010 19:04 / Updated on August 17, 2016 12:24